Medium pacer Hasan Ali took a maiden ten-wicket haul to help Pakistan win its first series against South Africa since 2003 with a 95-run victory in the second Test on the fifth and final day in Rawalpindi on Monday.
Hasan finished with 5-60 to record his best match figures of 11-114 and help dismiss South Africa -- who were set a daunting 370 to chase -- for 274 before the tea break.
Hasan's new-ball partner Shaheen Shah Afridi finished with 4-51, while spinner Yasir Shah took the last wicket to spark jubilation among the Pakistan players.
Opener Aiden Markram scored a fighting 108 and Temba Bavuma 61.
They put on a 106-run stand for the fourth wicket to give Pakistan a scare.
Markram took a single off the last ball before lunch as South Africa reached the break on 219-3, needing 151 for a win.
But Hasan ripped through the tourists' batting order, which lost seven wickets for just 33 runs with the second new ball.
Hasan struck with the second over of the new ball to end Markram's resistance by getting the opener caught in the slip and end his 335-minute fight.
Markram's fifth Test century -- the first outside South Africa -- included 13 boundaries and three sixes.
Next ball, Hasan had Quinton de Kock caught in the slip for nought, ending the South African skipper's miserable series with just 46 runs.
Pakistan skipper Babar Azam was delighted with the win.
"Thanks to South Africa for coming and playing competitive cricket," said Azam. "Hasan's comeback after one year was great and he showed great character."
Hasan was sidelined for more than a year with multiple injuries but came back strongly with 12 wickets in the series.
Azam admitted South Africa's resistance provided a tough challenge for his side.
"At one time, we thought the game could've gone either way when Markram and Bavuma were playing well. But we knew, one wicket and we can come back into the game again," he said.
Losing captain Quinton de Kock said his team lacked a killer touch.
"The first-innings deficit did play a big part," said de Kock. "We lost the big moments in the game and that cost us. It's painful at the moment.
"When we get back home, we'll have to look at our performances and improve on the way forward."
- Historic win -
Hasan dismissed George Linde for four to record his third five-wicket haul as he improved upon his previous best match figures of 7-83 against New Zealand in Abu Dhabi in 2018.
In the morning, both teams were involved in a keen battle for victory as South Africa resumed on 127-1, knowing the best chase at Rawalpindi Cricket Stadium in ten previous Tests was the 200 scored by Sri Lanka in 2000.
South Africa saw Dussen bowled off a beautiful inswinger by Hasan -- only the third ball of the day -- while Du Plessis was leg-before to the same bowler in the fifth over of the morning.
It capped a sub-par series for the experienced Du Plessis who managed just 55 in four innings.
This is Pakistan's only second Test series win over South Africa in 12 attempts, having lost eight and drawn three.
Pakistan last beat South Africa 1-0 in a two-match series at home in 2003.
Pakistan won the first Test by seven wickets in Karachi.
The series against South Africa -- who were touring Pakistan for the first time in 14 years -- is the biggest hosted by the home side since a deadly 2009 militant attack on Sri Lanka's squad in Lahore halted international tours.
The series win also lifts Pakistan to fifth in international Test rankings -- the first time they have placed in the top five since January 2017.
South Africa are pushed to sixth from fifth.
The two teams will now play three Twenty20 internationals on February 11, 13 and 14, all in Lahore.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.